Stock report · Delisted · Nasdaq
Intra-Cellular Therapies Inc (ITCI)
131.92USD Delisted Final close · Mar 31, 2025
ITCI no longer trades. Intra-Cellular Therapies was acquired by Johnson & Johnson (JNJ) on April 2, 2025.
All prices on this page are historical. The last trade was on March 31, 2025, at $131.92.
ITCI stock price history
Final trading statistics
- Final close
- $131.92
- Final trading day
- Mar 31, 2025
- Market cap at delisting
- $14.05B
- Shares outstanding
- 106.52M
- Final 52-week range
- $64.09 – $131.95
- Avg. volume (final 3 mo.)
- 3,179,505
- All-time high
- $131.92 · Mar 2025
- All-time low
- $7.26 · Oct 2019
- Return since IPO
- +1219.2%
- Beta
- 0.46
- Book value / share
- $10.81
- Price / book
- 12.20
About Intra-Cellular Therapies Inc
Intra-Cellular Therapies was a biopharmaceutical company that developed and sold small molecule drugs for central nervous system, neuropsychiatric and neurological disorders. Its product CAPLYTA treated schizophrenia and bipolar depression in adults and was sold through third-party drug wholesalers.
The company was founded in 2002 and based in Bedminster, New Jersey. Johnson & Johnson (JNJ) acquired it on April 2, 2025 for $132.00 in cash per share, after which it became part of Johnson & Johnson Innovative Medicine. The final trade was on March 31, 2025 at $131.92.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Bedminster, NJ
- Employees
- 860
- IPO date
- January 7, 2014
- Delisted
- April 2, 2025
- SEC CIK
- 1567514
Intra-Cellular Therapies financials before the delisting
The last 5 fiscal years Intra-Cellular Therapies reported as a public company, fiscal year ending December.
ITCI revenue and net income
ITCI earnings per share
ITCI annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $680.85M | −$74.7M | −$0.73 |
| FY2023 | $464.37M | −$139.7M | −$1.46 |
| FY2022 | $249.13M | −$256.3M | −$2.72 |
| FY2021 | $81.71M | −$284.1M | −$3.50 |
| FY2020 | $22.53M | −$227.0M | −$3.24 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Intra-Cellular Therapies stock FAQ
What happened to Intra-Cellular Therapies stock?
Intra-Cellular Therapies was acquired by Johnson & Johnson (JNJ) on April 2, 2025. The final close was $131.92 on March 31, 2025.
What did Intra-Cellular Therapies shareholders receive?
Each ITCI share was converted into $132.00 in cash. The deal was valued at about $14.6 billion.
Can I still buy ITCI stock?
No. ITCI is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on April 2, 2025.
What was the last price of ITCI?
ITCI last closed at $131.92 on March 31, 2025, which valued the company at about $14.05B.
How did Intra-Cellular Therapies do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Intra-Cellular Therapies reported revenue of $680.85M and net income of −$74.7M.
When did Intra-Cellular Therapies go public?
Intra-Cellular Therapies shares started trading on January 7, 2014.
ITCI no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.